AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12439553 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ml of hyperbaric 0.3% dibucaine
Number of subjects: 98
Study 12439553 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 98
Study 9934737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 271
Study 9934737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 271
Study 8520158 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lipid emulsion (group A)
Number of subjects: 30
Study 8520158 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose solution (group B)
Number of subjects: 30
Study 1967562 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (0.2 mg/kg)
Number of subjects: 24
Study 1967562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7002074 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) - total dose of 6.6 g over two weeks
Number of subjects: 40
Study 7002074 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate - one dose of 10 mg/kg body weight at ten-day intervals, three times
Number of subjects: 40
Study 31234717 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-Provera®
Number of subjects: 0
Study 31234717 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31314918 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 582
Study 31314918 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 582
Study 27709406 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power Program
Number of subjects: 112
Study 27709406 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 112
Study 26488913 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-oriented PSA video
Number of subjects: 0
Study 26488913 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatable disease-oriented video (beyondblue)
Number of subjects: 0
Study 26488913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23437972 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Daivobet® Gel)
Number of subjects: 579
Study 21781152 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin (5 mg once daily)
Number of subjects: 1058
Study 21781152 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1058
Study 19360866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent supported percutaneous coronary intervention (PCI)
Number of subjects: 100
Study 19360866 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization (CABG)
Number of subjects: 100
Study 17081285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination of multidisciplinary guidelines on prescribing behaviour
Number of subjects: 107
Study 17081285 — intervention group
Group type: COMPARATOR
Intervention: Control group of GPs not involved in guideline development
Number of subjects: 107
Study 15318467 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 200
Study 15318467 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Seal laryngeal mask
Number of subjects: 200
Study 11402631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tacrolimus 0.020 mg/kg IBW over 4 hours
Number of subjects: 6
Study 11402631 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus approximately 0.12 mg/kg IBW
Number of subjects: 6
Study 11402631 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tacrolimus 0.020 mg/kg over 4 hours (normal subjects)
Number of subjects: 6
Study 11402631 — intervention group
Group type: COMPARATOR
Intervention: Oral tacrolimus 5 mg (0.065 mg/kg) (normal subjects)
Number of subjects: 6
Study 9768401 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of aspirin intake (Group A)
Number of subjects: 61
Study 9768401 — intervention group
Group type: COMPARATOR
Intervention: Cessation of aspirin intake for 2 to 5 days before surgery (Group B)
Number of subjects: 61
Study 9768401 — intervention group
Group type: COMPARATOR
Intervention: Cessation of aspirin intake for 7 to 10 days before surgery (Group C)
Number of subjects: 61
Study 8314007 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 30
Study 8314007 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine Insulin (PI)
Number of subjects: 30
Study 3292105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil (12.5 to 75 mg b.i.d.)
Number of subjects: 401
Study 3292105 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (1 to 10 mg b.i.d.)
Number of subjects: 401
Study 3292105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 401
Study 3292105 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 401
Study 3292105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil and Prazosin
Number of subjects: 401
Study 8292068 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole
Number of subjects: 74
Study 8292068 — intervention group
Group type: COMPARATOR
Intervention: Butylscopolamine
Number of subjects: 74
Study 8292068 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 74
Study 359247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 161
Study 359247 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 161
Study 359247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 359247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 125 mg
Number of subjects: 161
Study 359247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg
Number of subjects: 161
Study 30290299 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline
Number of subjects: 1047
Study 30290299 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 1047
Study 27768399 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut Water (CW)
Number of subjects: 10
Study 27768399 — intervention group
Group type: COMPARATOR
Intervention: Water (PW)
Number of subjects: 10
Study 26400458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vercirnon 500 mg once daily
Number of subjects: 608
Study 26400458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vercirnon 500 mg twice daily
Number of subjects: 608
Study 26400458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 26400458 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (placebo, once daily, twice daily)
Number of subjects: 608
Study 24457277 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during primary PCI (aspiration group, n=33)
Number of subjects: 63
Study 24457277 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI without thrombus aspiration (non-aspiration group, n=30)
Number of subjects: 63
Study 22456864 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient led CGM
Number of subjects: 197
Study 22456864 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician driven CGM
Number of subjects: 197
Study 22456864 — intervention group
Group type: COMPARATOR
Intervention: Conventional self-monitoring of blood glucose (Control)
Number of subjects: 197
Study 19038406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine monotherapy
Number of subjects: 94
Study 19038406 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline and haloperidol combination
Number of subjects: 94
Study 17307427 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 to 60 mg, n = 177
Number of subjects: 349
Study 17307427 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 172
Number of subjects: 349
Study 17307427 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 to 60 mg
Number of subjects: 349
Study 17307427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 12774855 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 12 weeks
Number of subjects: 53
Study 12774855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day for 12 weeks
Number of subjects: 53
Study 12774855 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 53
Study 10952477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on day 1 and 200 mg on days 2-4)
Number of subjects: 12
Study 10952477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8979382 — intervention group
Group type: EXPERIMENTAL
Intervention: Success context
Number of subjects: 0
Study 8979382 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure context
Number of subjects: 0
Study 8979382 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly contingent relationship priming
Number of subjects: 0
Study 1487412 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN) 5.0 MU three times a week for one year
Number of subjects: 48
Study 1487412 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 48
Study 1487412 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2b (IFN)
Number of subjects: 48
Study 2857739 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg by dry powder inhalation)
Number of subjects: 16
Study 2857739 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mcg by pressurized aerosol)
Number of subjects: 16
Study 2857739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mg lactose by dry powder inhalation)
Number of subjects: 16
Study 31232179 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 21189
Study 31232179 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 21189
Study 31232179 — intervention group
Group type: COMPARATOR
Intervention: Control (poster and traditional brochure)
Number of subjects: 21189
Study 28543642 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-CPB
Number of subjects: 100
Study 28543642 — intervention group
Group type: COMPARATOR
Intervention: On-CPB
Number of subjects: 100
Study 26422466 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded visit with questions modeled after a CIM consultation
Number of subjects: 24
Study 26422466 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidil
Number of subjects: 24
Study 26422466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26422466 — intervention group
Group type: COMPARATOR
Intervention: Standard visit based on an empathic conventional primary care evaluation
Number of subjects: 24
Study 23642006 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser CCI (2.75-mm three-plane)
Number of subjects: 14
Study 23642006 — intervention group
Group type: COMPARATOR
Intervention: Manual CCI (2.75-mm using disposable angled knives)
Number of subjects: 14
Study 21501334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 40mg
Number of subjects: 15
Study 21501334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19901122 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly cycled tandem high-dose therapy (HD); 2 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² every 14 days, followed by 2 cycles of epirubicin 90 mg/m², cyclophosphamide 3000 mg/m², and thiotepa 400 mg/m² every 21 days.
Number of subjects: 211
Study 19901122 — intervention group
Group type: EXPERIMENTAL
Intervention: High YB-1 patients receiving HD
Number of subjects: 211
Study 19901122 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose-dense chemotherapy (DD); 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m², followed by 3 cycles of cyclophosphamide 600 mg/m², methotrexate 40 mg/m², and fluorouracil 600 mg/m² every 14 days.
Number of subjects: 211
Study 19901122 — intervention group
Group type: EXPERIMENTAL
Intervention: High YB-1
Number of subjects: 211
Study 18034211 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg IV once daily followed by oral moxifloxacin 400 mg once daily
Number of subjects: 161
Study 18034211 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g IV once daily followed by oral cefuroxime axetil 500 mg twice daily
Number of subjects: 161
Study 15308999 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menopausal hormone therapy
Number of subjects: 397
Study 15308999 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 397
Study 11403816 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory discrimination training
Number of subjects: 0
Study 11403816 — intervention group
Group type: COMPARATOR
Intervention: Control group (medically treated patients)
Number of subjects: 0
Study 9253136 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape modeling smoking cessation
Number of subjects: 60
Study 9253136 — intervention group
Group type: COMPARATOR
Intervention: Brief smoking cessation advice and tipsheet
Number of subjects: 60
Study 7802493 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined burrow destruction and removal of chenopods in Karameh
Number of subjects: 0
Study 7802493 — intervention group
Group type: COMPARATOR
Intervention: Control group in Sweimeh
Number of subjects: 0
Study 3092967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth salicylate
Number of subjects: 50
Study 3092967 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 50
Study 3092967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31106491 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal lipid-based nutrient supplements (LNS)
Number of subjects: 4011
Study 31106491 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 4011
Study 26482244 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion skin extract powder (approximately 163 mg quercetin)
Number of subjects: 12
Study 26482244 — intervention group
Group type: COMPARATOR
Intervention: Pure quercetin dihydrate (134 mg quercetin aglycone equivalent)
Number of subjects: 12
Study 23183440 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg twice a day plus tenofovir-emtricitabine (TDF/FTC) 300 mg/200 mg once daily
Number of subjects: 38
Study 23183440 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (RAL) twice a day plus TDF/FTC (from QDMRK study)
Number of subjects: 38
Study 21723096 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 50mg
Number of subjects: 21
Study 21723096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 19855308 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weight squat
Number of subjects: 6
Study 19855308 — intervention group
Group type: COMPARATOR
Intervention: Smith machine squat
Number of subjects: 6
Study 18200771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0
Study 15117503 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine penicillin
Number of subjects: 31
Study 15117503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 31
Study 10886122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of lefradafiban
Number of subjects: 12
Study 10886122 — intervention group
Group type: COMPARATOR
Intervention: Jejunal administration of lefradafiban
Number of subjects: 12
Study 10886122 — intervention group
Group type: COMPARATOR
Intervention: Ileal administration of lefradafiban
Number of subjects: 12
Study 10886122 — intervention group
Group type: COMPARATOR
Intervention: Colonic administration of lefradafiban
Number of subjects: 12
Study 10886122 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion after oral, jejunal, and ileal applications
Number of subjects: 12
Study 10886122 — intervention group
Group type: COMPARATOR
Intervention: Urinary excretion after rectal administration
Number of subjects: 12
Study 9040998 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear array EUS
Number of subjects: 79
Study 9040998 — intervention group
Group type: COMPARATOR
Intervention: Radial scanning EUS
Number of subjects: 79
Study 8201373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 127
Study 8201373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 3477355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists with experience in treating fearful children
Number of subjects: 24
Study 3477355 — intervention group
Group type: COMPARATOR
Intervention: Dentists without experience in treating fearful children
Number of subjects: 24
Study 29333843 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification bracelet placed on the forearm
Number of subjects: 914
Study 29333843 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification bracelet placed on the leg
Number of subjects: 914
Study 27232153 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg Lercanidipine (LER)
Number of subjects: 59
Study 26631224 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMBA model for integrated OA care, including physiotherapist-led patient OA education sessions and an exercise programme lasting 8-12 weeks.
Number of subjects: 0
Study 26631224 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMBA model for integrated OA care
Number of subjects: 0
Study 26631224 — intervention group
Group type: COMPARATOR
Intervention: Usual OA care
Number of subjects: 0
Study 23177313 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (high-dose)
Number of subjects: 215
Study 23177313 — intervention group
Group type: COMPARATOR
Intervention: 20 mg atorvastatin (low-dose)
Number of subjects: 215
Study 21684096 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236
Study 21684096 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 236
Study 18444791 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin (10 mg/kg intravenously every 24 h)
Number of subjects: 1867
Study 18444791 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g intravenously every 12 h)
Number of subjects: 1867
Study 18444791 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1867
Study 18444791 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1867
Study 16818273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg
Number of subjects: 71
Study 16818273 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO) 40 mg/kg
Number of subjects: 71
Study 16818273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (10 or 20 mg/kg)
Number of subjects: 71
Study 16818273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 71
Study 14501611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (50 microg/day) and medroxyprogesterone acetate (10 mg/day) for 12 days per cycle
Number of subjects: 50
Study 14501611 — intervention group
Group type: COMPARATOR
Intervention: Untreated women (control group)
Number of subjects: 50
Study 11126524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 mg once a day) for 4 weeks, followed by 20 mg once a day for non-responders for an additional 4 weeks
Number of subjects: 83
Study 11126524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11126524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 mg once a day)
Number of subjects: 83
Study 8568271 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg cA2
Number of subjects: 0
Study 8568271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg cA2
Number of subjects: 0
Study 8568271 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2
Number of subjects: 0
Study 2156984 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 102
Study 2156984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 7006664 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cyclophosphamide (CY)
Number of subjects: 485
Study 7006664 — intervention group
Group type: COMPARATOR
Intervention: oral melphalan with prednisone (M & P)
Number of subjects: 485
Study 7006664 — intervention group
Group type: COMPARATOR
Intervention: 4-drug regimen
Number of subjects: 485
Study 7006664 — intervention group
Group type: EXPERIMENTAL
Intervention: azathioprine and vincristine
Number of subjects: 485
Study 7006664 — intervention group
Group type: COMPARATOR
Intervention: stop all treatment until evidence of relapse
Number of subjects: 485
Study 31743788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion (ATD)
Number of subjects: 30
Study 31743788 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan supplementation (TRYP+)
Number of subjects: 30
Study 31155516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laparoscopic-vaginal radical hysterectomy
Number of subjects: 1952
Study 28699499 — intervention group
Group type: EXPERIMENTAL
Intervention: Argan oil (30 ml per day for 8 weeks)
Number of subjects: 100
Study 28699499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 26153168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cream mixed of yogurt and honey
Number of subjects: 70
Study 26153168 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal cream
Number of subjects: 70
Study 21682844 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 20
Study 21682844 — intervention group
Group type: COMPARATOR
Intervention: Twist drills
Number of subjects: 20
Study 21300929 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751 with pemetrexed (200 mg)
Number of subjects: 171
Study 21300929 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pemetrexed
Number of subjects: 171
Study 21300929 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-751 with pemetrexed
Number of subjects: 171
Study 19171808 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 136
Study 19171808 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise
Number of subjects: 136
Study 19171808 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 136